Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Gower Publishing

Daiichi Sankyo logo

Daiichi Sankyo starts mirogabalin trial in spinal injury pain

Trial will enrol 274 subjects with post-spinal cord injury neuropathic pain

- PMLiVE

UK business: Brexit deadlock causing “frustration and anger”

Pharma must still plan for no-deal, only slightly later

- PMLiVE

NICE recommends MSD’s diabetes drug Steglatro

MSD offering lowest price to win share of SGLT-2 inhibitor market

- PMLiVE

NICE green light for Imfinzi in groundbreaking early lung cancer treatment

Early treatment opens up possibility of cure

- PMLiVE

FDA approves Novartis’ next-gen MS drug Mayzent

Drug reduces risk of disease progression

- PMLiVE

Genfit launches $135m IPO to back NASH plans

Trailing rivals Intercept in race to market

- PMLiVE

Trump takes aim at Obamacare with repeal move

Aims to dismantle the programme

- PMLiVE

Lilly and ImmuNext deal focused on autoimmune diseases

Aiming for targets upstream of existing checkpoint regulators

Celgene building

Celgene hopes for second time lucky for ozanimod FDA filing

One of six key drugs for BMS-Celgene merger

- PMLiVE

Setback for Vertex’s cystic fibrosis challenger Proteostasis

Unlikely to match market leader's triple therapy

- PMLiVE

Aimmune preps EU filing for peanut allergy immunotherapy

Company set to be first to market

- PMLiVE

Bluebird plays down report of EU gene therapy approval

Charity says Zynteglo (LentiGlobin) has already achieved a conditional marketing authorisation

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links